21st Aug 2017 07:06
PRESS RELEASE
FOR IMMEDIATE RELEASE
CEL-SCI Corporation issues restricted shares to Ergomed for partial settlement of receivable
London, UK - 21 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that it has entered into an agreement with its co-development partner, CEL-SCI Corporation (NYSE: CVM) ('CEL-SCI'), whereby CEL-SCI will issue 480,000 shares of restricted stock which, upon registration, may be sold subject to a volume restriction of no more than five per cent of the trading volume in any single day.
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 503205 | |
Dan Weng (Chief Executive Officer) | ||
Stephen Stamp (Chief Financial Officer) | ||
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 | |
Michael Meade / Freddie Barnfield (Nominated Adviser) | ||
James Black (Joint Broker) | ||
N+1 Singer | Tel: +44 (0) 20 7496 3000 | |
Alex Price (Joint Broker) | ||
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 | |
Chris Gardner / Mary-Jane Elliott Ivar Milligan / Philippa Gardner | ||
MC Services - for Continental European enquiries | Tel: +49 211 5292 5222 | |
Anne Hennecke | ||
About Ergomed
Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com
Related Shares:
ERGO.L